239 related articles for article (PubMed ID: 27528054)
41. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors.
Hamadeh HK; Todd M; Healy L; Meyer JT; Kwok AM; Higgins M; Afshari CA
Chem Res Toxicol; 2010 Jun; 23(6):1025-33. PubMed ID: 20521778
[TBL] [Abstract][Full Text] [Related]
42. A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
Zhao L; Yuan X; Wang J; Feng Y; Ji F; Li Z; Bian J
Bioorg Med Chem; 2019 Mar; 27(5):677-685. PubMed ID: 30733087
[TBL] [Abstract][Full Text] [Related]
43. Evolving molecular-based targeted therapy for cancer: an exciting field.
Carneiro B; Hsiao K; Khandekar J
Compr Ther; 2005; 31(4):299-305. PubMed ID: 16407611
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
45. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
46. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
47. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
48. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eskens FA; Verweij J
Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
[TBL] [Abstract][Full Text] [Related]
49. An update on epidermal growth factor receptor inhibitors.
Modi S; Seidman AD
Curr Oncol Rep; 2002 Jan; 4(1):47-55. PubMed ID: 11734113
[TBL] [Abstract][Full Text] [Related]
50. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
51. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
52. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
53. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
[TBL] [Abstract][Full Text] [Related]
54. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
Zhang C; Tan C; Ding H; Xin T; Jiang Y
Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
[TBL] [Abstract][Full Text] [Related]
55. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
56. Past, present and future of targeted therapy in solid tumors.
Palazzo A; Iacovelli R; Cortesi E
Curr Cancer Drug Targets; 2010 Aug; 10(5):433-61. PubMed ID: 20384576
[TBL] [Abstract][Full Text] [Related]
57. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
58. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
59. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
60. The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.
Ntanasis-Stathopoulos I; Fotopoulos G; Tzanninis IG; Kotteas EA
Cancer Invest; 2016 Aug; 34(7):313-39. PubMed ID: 27486869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
